Pascal Deschatelets, Chief Scientific Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 24,000 shares at $42.87 ($1.0M) on 2023-09-08, disclosed to the SEC on 2023-09-11.
Scheduled sale ($1.0M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.87 | 12,000 | $514K | 50.0% |
| 2 | $42.87 | 12,000 | $514K | 50.0% |
| Total | $42.87 avg | 24,000 | $1.0M | 100% |
| Filing → |
| APLS | SELL | 2026-01-15 | $51K | — | Filing → |
| APLS | SELL | 2025-01-30 | $24K | — | Filing → |
| APLS | SELL | 2025-01-23 | $240K | — | Filing → |